Shandong Cancer Hospital proton center joins FlashForward Consortium for flash proton therapy research

Huge Two-Day Clean Sweep Auction July 24-25th. Click Here to Bid!

advertisement
Posição atual:
>
>
> This Story

Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Rad Oncology Homepage

Elekta Unity MR-Linac receives clearance from the Canadian Nuclear Safety Commission

Many of the deadliest cancers receive the least amount of research funding

Swiss Medical Network advances cancer care in Switzerland with multi-system agreement for Accuray radiation therapy systems

MVZ Prof. Dr. Uhlenbrock and Partner select C-RAD’s SIGRT solution

Cyclotron rigging completed in Guangzhou, Guangdong Province, China

Radsource completes 16 ProtonPACS installations in Q2: 2019

RaySearch and Vision RT announce strategic partnership

Sun Nuclear to showcase key quality management advances at AAPM 2019

Elekta to demonstrate leadership in precision radiation medicine at AAPM with launch of new QA portfolio

Johns Hopkins Medicine researchers identify health conditions likely to be misdiagnosed

Shandong Cancer Hospital proton center joins FlashForward Consortium for flash proton therapy research

Press releases may be edited for formatting or style
PALO ALTO, Calif., June 12, 2019 /PRNewswire/ -- Varian (NYSE: VAR) today announced the Proton Clinical Research Center of the Shandong Cancer Hospital, is the first center in Asia Pacific to join the FlashForward™ Consortium. The Consortium now includes 15 institutions and is focused on preclinical research, clinical implementation, and advocacy efforts for FLASH Therapy.

FLASH Therapy is an experimental non-invasive treatment modality using an external beam delivered in high doses, at ultra-high speeds (less than 1 second), and in one to three sessions. It represents an exciting and potentially promising new direction in the treatment of cancer.

Story Continues Below Advertisement

THE (LEADER) IN MEDICAL IMAGING TECHNOLOGY SINCE 1982. SALES-SERVICE-REPAIR

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.



At the American Association for Cancer Research (AACR) Annual Meeting in Atlanta, GA earlier this year, Varian presented publicly the first pre-clinical results of its research on FLASH in partnership with the University of Maryland School of Medicine's Department of Radiation Oncology and the Maryland Proton Treatment Center. The FLASH Therapy preclinical tests showed reduced toxicity in healthy tissues and organs, compared to conventional proton treatments, displaying 25-30 percent less damage to lung tissue, resulting in less fibrosis of the lung, and an average of 35 percent reduction in skin dermatitis during treatment. The tests, in mice models, were conducted on a modified clinical device capable of translation to humans.

"We are aiming to build a first-class proton therapy center, training and research base," said Professor Yu Jinming, Academician of Chinese Academy of Engineering and president of Shandong Cancer Hospital & Institute. "We are happy to join the Consortium and be involved in the research and development programs of this leading technology that could potentially provide improved clinical solutions for patients."

"We are pleased to welcome the Proton Clinical Research Center of the Shandong Cancer Hospital to this advanced research group," said Kolleen Kennedy, chief growth officer and president of Proton Therapy Solutions, Varian. "We look forward to their perspectives as the first member from APAC to this important research and development effort."


About Varian
Varian is a leader in developing and delivering cancer care solutions and is focused on creating a world without fear of cancer. Headquartered in Palo Alto, California, Varian employs approximately 7,000 people around the world. For more information, visit www.varian.com and follow @VarianMedSys on Twitter.

Back to HCB News
  Pages: 1

Rad Oncology Homepage


You Must Be Logged In To Post A Comment